JP2023537600A - がんを処置するための複製ストレス経路剤組成物および方法 - Google Patents

がんを処置するための複製ストレス経路剤組成物および方法 Download PDF

Info

Publication number
JP2023537600A
JP2023537600A JP2023510340A JP2023510340A JP2023537600A JP 2023537600 A JP2023537600 A JP 2023537600A JP 2023510340 A JP2023510340 A JP 2023510340A JP 2023510340 A JP2023510340 A JP 2023510340A JP 2023537600 A JP2023537600 A JP 2023537600A
Authority
JP
Japan
Prior art keywords
tumor
ecdna
cells
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023510340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537600A5 (https=
Inventor
ハッシグ，クリスティアン
ハンセン，リャン
ミルティノヴィッチ，スネジャナ
クリスティアンセン，ジェイソン
ホーンビー，ザカリー
チョードリー，スディール
セレステ，アンソニー
ターナー，クリステン
ウィルキンソン，ディープティ
Original Assignee
バウンドレス バイオ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バウンドレス バイオ，インク． filed Critical バウンドレス バイオ，インク．
Publication of JP2023537600A publication Critical patent/JP2023537600A/ja
Publication of JP2023537600A5 publication Critical patent/JP2023537600A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023510340A 2020-08-12 2021-08-11 がんを処置するための複製ストレス経路剤組成物および方法 Pending JP2023537600A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063064555P 2020-08-12 2020-08-12
US63/064,555 2020-08-12
US202163168120P 2021-03-30 2021-03-30
US63/168,120 2021-03-30
PCT/US2021/045556 WO2022035970A1 (en) 2020-08-12 2021-08-11 Replication stress pathway agent compositions and methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2023537600A true JP2023537600A (ja) 2023-09-04
JP2023537600A5 JP2023537600A5 (https=) 2024-08-20

Family

ID=80247345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510340A Pending JP2023537600A (ja) 2020-08-12 2021-08-11 がんを処置するための複製ストレス経路剤組成物および方法

Country Status (11)

Country Link
US (3) US11547711B2 (https=)
EP (1) EP4196614A4 (https=)
JP (1) JP2023537600A (https=)
KR (1) KR20230098134A (https=)
CN (1) CN116368243A (https=)
AU (1) AU2021325905A1 (https=)
BR (1) BR112023002453A2 (https=)
CA (1) CA3187760A1 (https=)
MX (1) MX2023001717A (https=)
TW (1) TW202221118A (https=)
WO (1) WO2022035970A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187760A1 (en) 2020-08-12 2022-02-17 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
WO2022152899A1 (en) * 2021-01-18 2022-07-21 Gbg Forschungs Gmbh Method for predicting the response to cdk4/6 inhibitor therapy in cancer patients
BR112023024571A2 (pt) 2021-05-27 2024-02-06 Boundless Bio Inc Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用
WO2024059696A1 (en) * 2022-09-15 2024-03-21 Recurium Ip Holdings, Llc Combinations
CN116083576B (zh) * 2022-12-07 2024-01-30 上海市临床检验中心 一种基于CRISPR/Cas12a的KRAS热点基因突变检测系统和方法
WO2025049814A2 (en) * 2023-09-01 2025-03-06 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use
WO2025184572A1 (en) * 2024-03-01 2025-09-04 Zeno Management, Inc. Wee1 inhibitor combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165458A1 (en) * 2018-02-26 2019-08-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567007A (en) 1979-06-29 1981-01-24 Toshiba Corp Coating film thickness measuring apparatus
US12559789B2 (en) * 2017-01-20 2026-02-24 The Jackson Laboratory Method of targeting patient-specific oncogenes in extrachromosomal DNA to treat glioblastoma
JP7273791B2 (ja) * 2017-04-10 2023-05-15 シエラ オンコロジー， インコーポレイテッド 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
US11193164B2 (en) * 2017-05-24 2021-12-07 The Regents Of The University Of California Methods of diagnosing and treating cancer targeting extrachromosomal DNA
CA3065803A1 (en) * 2017-06-01 2018-12-06 Sierra Oncology, Inc. Biomarkers and patient selection strategies
EP3709981A4 (en) * 2017-11-15 2021-08-11 The Regents of the University of California METHOD OF TREATMENT OF EXTRACHROMOSOMAL DNA EXPRESSING CANCER
US20220010307A1 (en) * 2018-12-10 2022-01-13 The Regents Of The University Of California Compositions and methods for modulating transcriptional activity of amplified oncogenes contained on extrachromosomal dna
WO2020227255A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of Michigan Targeted therapy
CA3187760A1 (en) * 2020-08-12 2022-02-17 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer
BR112023024571A2 (pt) 2021-05-27 2024-02-06 Boundless Bio Inc Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos
WO2023043938A1 (en) 2021-09-17 2023-03-23 Boundless Bio, Inc. Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof
JP2024534420A (ja) 2021-09-17 2024-09-20 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
US20230272485A1 (en) 2022-02-16 2023-08-31 Boundless Bio, Inc. Replication stress pathway agent compositions and methods for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165458A1 (en) * 2018-02-26 2019-08-29 Sierra Oncology, Inc. Methods of treatment of cancer comprising chk1 inhibitors

Also Published As

Publication number Publication date
AU2021325905A1 (en) 2023-04-13
US11642345B2 (en) 2023-05-09
US20230248728A1 (en) 2023-08-10
US12246017B2 (en) 2025-03-11
EP4196614A1 (en) 2023-06-21
MX2023001717A (es) 2023-04-13
BR112023002453A2 (pt) 2023-05-02
TW202221118A (zh) 2022-06-01
US11547711B2 (en) 2023-01-10
EP4196614A4 (en) 2024-12-18
WO2022035970A1 (en) 2022-02-17
US20230078903A1 (en) 2023-03-16
CN116368243A (zh) 2023-06-30
KR20230098134A (ko) 2023-07-03
US20220143022A1 (en) 2022-05-12
CA3187760A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP2023537600A (ja) がんを処置するための複製ストレス経路剤組成物および方法
JP6742391B2 (ja) 併用療法
JP7536320B2 (ja) Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
CN111032082B (zh) Her2阳性癌症的治疗
JP2022537384A (ja) ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
TW202521120A (zh) 藥物組合物及其應用
CA2990703A1 (en) Biomarkers for nanoparticle compositions
JP7504097B2 (ja) Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法
Fang et al. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
JP2022544485A (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
CN115867669A (zh) 监测kras突变的方法
WO2023235716A2 (en) Cancer treatment using topoisomerase i inhibitors and plk1 inhibitors
Blay et al. Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
CN115397415A (zh) 乳腺癌治疗剂
WO2023091932A1 (en) Cancer treatment using lsd1 inhibitors and plk1 inhibitors
AU2020326612B2 (en) Treatment of canine cancers
US20260076970A1 (en) Cancer treatment using mtdp inhibitors and plk1 inhibitors
AU2024356380A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
US11957677B2 (en) Cancer treatment using FGFR inhibitors and PLK1 inhibitors
CN119604291A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
US20220071941A1 (en) Therapies for squamous cell carcinomas
WO2025049904A1 (en) Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation
HK40124174A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
HK40102675A (zh) 索托拉西布给药方案

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260324